Wipro Limited, a leading global information technology, consulting and business process services company today announced that it has 
been positioned as a Leader by technology global advisory research firm International Data Corporation (IDC) in its report ‘IDC MarketScape Worldwide Life Science Sales and Marketing Digital Transformation Vendor Assessment’ (doc #US40510716, July 2016).
IDC evaluated 13 prominent consulting and service providers in the area of digital transformation in life sciences sales and marketing, including those that transform sales and marketing operating models, leadership, work sources and collaboration, omni-channel optimization, and new ways of collecting, aggregating, and analysing digital information. The report describes successful vendors as companies “demonstrating deep, proven industry-specific expertise, with a strong book of references, proven understanding of industry regulations and compliance standards, and willingness to provide dedicated resources onsite on an ongoing basis across sequential digital projects to maintain acquired best practices.”
The report notes that Wipro has received customer appreciation for its life sciences industry expertise, account management and technical capabilities. It also states that the company has extensive experience with life sciences establishments, over 10,000 dedicated life sciences employees and multiple delivery centers across four continents – US, Europe, Australia and Asia.
Elaborating on Wipro’s vision for Healthcare & Life Sciences, Jeffery Heenan Jalil, Senior Vice President, Healthcare, Life Sciences & Services, Wipro Limited said, “The recognition by IDC is a testament to our expertise and investments in remodelling care delivery for our clients for a common good: improving the health and lives of individuals and the wellness of entire populations. Healthcare, today is fragmented, reactive, unintelligent and disconnected. We believe there is considerable scope to improve healthcare through increasing patient engagement and quality of care, reducing costs, and improving the patient experience and clinical research effectiveness.”
